Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy combined with L19-IL2 immunotherapy in metastatic non-small cell lung cancer
ISRCTN49817477Phase 2Completed
- Sponsor
- Maastricht University
- Start
- Apr 2019
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of darleukin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Maastricht University. Primary endpoint: Progression-free survival at 1.5 years. Started Apr 2019; status: completed.
02
Drugs
darleukin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN49817477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN49817477.